|Mr. David A. Ricks||Chairman, CEO & Pres||4.1M||N/A||1968|
|Ms. Anat Ashkenazi||Sr. VP & CFO||1.91M||N/A||1972|
|Dr. Daniel M. Skovronsky M.D., Ph.D.||Sr. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Labs||2.16M||N/A||1974|
|Mr. Diogo Rau||Sr. VP & Chief Information and Digital Officer||1.06M||N/A||N/A|
|Mr. Jacob S. Van Naarden||Sr. VP, CEO of Loxo Oncology & Pres of Lilly Oncology||2.01M||N/A||1985|
|Mr. Donald A. Zakrowski||Chief Accounting Officer & VP of Fin.||N/A||N/A||N/A|
|Mr. Martin Bott MIBS||VP of Fin. & Special Projects||N/A||N/A||1963|
|Ms. Anat Hakim J.D.||Sr. VP, Gen. Counsel & Sec.||N/A||N/A||1969|
|Mr. Alonzo Weems||Sr. VP and Chief Ethics & Compliance Officer||N/A||N/A||N/A|
|Ms. Leigh Ann Pusey||Sr. VP of Corp. Affairs & Communications||N/A||N/A||1963|
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly and Company’s ISS governance QualityScore as of 1 February 2023 is 5. The pillar scores are Audit: 3; Board: 5; Shareholder rights: 9; Compensation: 2.